John M. Levenick, MD, from the Penn State Hershey Medical Center, and colleagues conducted a prospective trial of 449 patients undergoing ECRP. Patients were randomized to a single dose of rectal indomethacin or a placebo suppository.
Here are three points:
1. The researchers found between 7.2 percent and 4.9 percent of patients in the indomethacin and placebo groups, respectively, developed pancreatitis.
2. Between the groups, complications and pancreatitis’ severity were similar.
3. The study was stopped early owing to futility per a priori protocol guidelines.
More articles on GI & endoscopy:
Gastroenterologist to know: Dr. Steven Abo of the University of Pittsburgh
Depression, somatization linked to postprandial symptoms in IBS patients — 5 points
Researchers find differences in colonoscopy quality — 4 points
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.